# Alpha Cognition

Alpha Cognition is an Asset Manager.

## Overview

- **Organization type:** Asset Manager
- **Assets under management:** Undisclosed
- **Website:** alphacognition.com

## Regulatory record

- **Reports private funds:** No

## About

Listed on the NASDAQ: ACOG | Alpha Cognition is a clinical stage, biopharmaceutical company dedicated to developing novel treatments for under-served neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis (ALS). ALPHA-1062, a patented new chemical entity that has demonstrated safety and improved tolerability in human clinical trials. It is being developed as a new acetylcholine esterase inhibitor for the treatment of dementia of the Alzheimer’s type, with minimal gastrointestinal side-effects and novel routes of administration.

## Questions

### How is Alpha Cognition funded?

As a publicly traded company, Alpha Cognition funds operations through equity sales in the capital markets. It does not raise capital through limited partner commitments, a fund-of-funds model, or family-office allocations. The burn rate is tied to regulatory and clinical-development milestones, with no diversified investment portfolio to offset risk.

### Does Alpha Cognition have a investment portfolio or private-equity mandate?

No. The company holds no disclosed minority positions in portfolio companies, real-asset interests, or fund-of-fund commitments. Its balance sheet reflects cash reserves and operational assets associated with a pre-revenue biotech development program, not an investment portfolio.

## Related profiles

- [Atlas Lithium](https://altss.com/profile/atlas-lithium-corp)
- [Ascent Industries Co.](https://altss.com/profile/ascent-industries-co)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/alpha-cognition-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology